FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Improvement in Health-Related Quality of Life in Patients with Moderate to Severe Crohn's Disease Treated with Risankizumab vs Ustekinumab in the Phase 3B SEQUENCE Study. PMID 42085631 · Am J Gastroenterol · 2026-May-05 The study is a Phase 3b randomized trial of drug interventions (risankizumab vs ustekinumab) in humans and reports original primary results. However, it is not an oncology study (focus is Crohn's disease) and its endpoints are quality-of-life (IBDQ, SF-36) and symptom improvements, not the required time-to-event efficacy endpoints. |
S
B
|
严格 v3 独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies. PMID 41838419 · Rheumatology (Oxford) · 2026-May-05 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Phase 2b trial of an oral relaxin family peptide receptor 1 agonist in patients with chronic heart failure: rationale and design. PMID 41711202 · ESC Heart Fail · 2026-May-05 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Current and emerging therapies in IDH-mutant glioma. PMID 42085879 · Neurotherapeutics · 2026-May-04 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| NH600001, an etomidate analogue, provides gastrointestinal endoscopy sedation/anesthesia and reduces adrenocortical depression: two randomized controlled trials. PMID 42082491 · Nat Commun · 2026-May-04 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma. PMID 42082272 · J Immunother Cancer · 2026-May-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Phase II trial of combination radiation, hormone, and immunotherapy in grade group 5 prostate cancer. PMID 42082271 · J Immunother Cancer · 2026-May-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Renin-Angiotensin System Inhibitors in Long-Term Oncologic Outcomes of Patients With Stage II/III Colon Cancer and Hypertension: A Target Trial Emulation. PMID 42081750 · JCO Oncol Pract · 2026-May-04 The study is a retrospective observational cohort, not a randomized controlled trial. It does not meet the required criteria for a Phase III/IIIb or Phase II/III randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| From diabetes to tumor growth: unravelling the impact of glucose-lowering therapies. PMID 42081011 · Endocrine · 2026-May-04 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Intraoperative endoscopic pylorus dilatation during minimally invasive Ivor Lewis oesophagectomy to prevent delayed gastric conduit emptying (DGCE): protocol for the WIDE randomised controlled trial. PMID 42082244 · BMJ Open · 2026-May-03 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Hematoma Interleukin-1 Receptor Antagonist Concentrations Predict Long-Term Outcome in Acute Human Intracerebral Hemorrhage. PMID 42071280 · Ann Neurol · 2026-May-03 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Doublet versus triplet therapy in Indian patients with locally advanced & metastatic gall bladder cancer: a randomised trial. PMID 42069801 · Sci Rep · 2026-May-02 The record is an oncology randomized trial with drug interventions and primary time-to-event endpoints (PFS, OS). However, the explicit trial phase (III/IIIb or II/III) is not provided in the title, abstract, or metadata, and the deterministic review signals phase3 as false. Therefore, the 'phase3_or_definitive' criterion cannot be established, making the report ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial. PMID 42030965 · Lancet · 2026-May-02 未发现恶性肿瘤人群证据。 |
H
L
B
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST). PMID 41880871 · Eur J Cancer · 2026-May-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Survival modelling of relapse-free survival and competing-risk analysis in patients with high-risk localized prostate cancer treated in GETUG-12. PMID 41855781 · Eur J Cancer · 2026-May-02 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Stereotactic body radiotherapy versus hepatic resection for recurrent small hepatocellular carcinoma: A post-hoc analysis with propensity score adjustment from two randomized trials. PMID 41833569 · Eur J Cancer · 2026-May-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Tumor burden in metastatic colorectal cancer quantified using deep learning models: Prognostic value and maintenance treatment benefit in the CAIRO3 trial. PMID 41819026 · Eur J Cancer · 2026-May-02 The record is from a randomized, drug-intervention, oncology trial with time-to-event endpoints, but the specific analysis presented is an exploratory biomarker subgroup analysis, not the primary or key secondary result of the trial. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| De-Escalated Adjuvant Radiation Therapy in Patients With HPV-Positive Oropharyngeal Cancer. PMID 42149594 · JAMA Netw Open · 2026-May-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 2 Figure · 5 Panel · risk visible |
| Vunakizumab for Radiographic Axial Spondyloarthritis: A Randomized Clinical Trial. PMID 42101839 · JAMA Netw Open · 2026-May-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Tr14 gel compared to diclofenac gel after acute unilateral ankle sprain: an Individual Patient Data (IPD) meta-analysis of two multi-center trials. PMID 42067889 · BMC Musculoskelet Disord · 2026-May-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Biosimilar anti-vascular endothelial growth factor agents: Clinical outcomes, safety, and cost-effectiveness in India. PMID 42054089 · Indian J Ophthalmol · 2026-May-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant chemotherapy for soft-tissue sarcoma of the extremities: A post-hoc Sarculator-based risk analysis of the EORTC 62961-ESHO 95 randomized trial. PMID 42035475 · Cancer · 2026-May-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies. PMID 41974026 · Hepatol Commun · 2026-May-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Robustness of highly purified eicosapentaenoic acid trials and their cardiovascular outcomes. PMID 41870913 · J Cardiovasc Med (Hagerstown) · 2026-May-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Nutritional supplements: current evidence for retinitis pigmentosa and Stargardt disease. PMID 41861379 · Curr Opin Ophthalmol · 2026-May-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Tavapadon as Adjunctive Treatment for Parkinson Disease: The TEMPO-3 Randomized Clinical Trial. PMID 41860544 · JAMA Neurol · 2026-May-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Fixed-Dose Tavapadon for Early Parkinson Disease: A Randomized Clinical Trial. PMID 41860533 · JAMA Neurol · 2026-May-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial. PMID 41854603 · JAMA Oncol · 2026-May-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Neoadjuvant Immunotherapy and Chemoimmunotherapy Regimens in Head and Neck Cancer: A Systematic Review and Meta-Analysis. PMID 41817516 · JAMA Otolaryngol Head Neck Surg · 2026-May-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| More Questions Than Answers in Trial of GRAIL's Galleri. PMID 41817436 · Cancer Discov · 2026-May-01 The record describes a randomized, controlled trial of a diagnostic test (Galleri) for early cancer detection, not a therapeutic drug intervention. The primary endpoint is a reduction in late-stage cancers, which is not a time-to-event efficacy endpoint (like OS, PFS, etc.) as required. Phase is not definitively established as Phase III/IIIb or Phase II/III. Therefore, it is ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Characteristics of Participants Screened and Randomized to the Melanoma Self Surveillance Trial. PMID 41811339 · JAMA Dermatol · 2026-May-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Outcomes of Older Adults With Advanced Cancer Who Prefer Quality of Life vs Prolonging Survival: A Secondary Analysis of the GAP70+ Cluster Randomized Clinical Trial. PMID 41784985 · JAMA Oncol · 2026-May-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant Chemotherapy vs Upfront Surgery in Patients With Locally Advanced Colon Cancer: A Randomized Clinical Trial. PMID 41779406 · JAMA Surg · 2026-May-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: a multicenter, randomized, double-blind, phase 3A clinical trial (NIMBLE). PMID 41738176 · Am J Respir Crit Care Med · 2026-May-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Spatially resolved transcriptomics identifies tumor-stroma-immune networks and therapeutic targets in endocrine-resistant advanced breast cancer treated with Everolimus+Letrozole: insights from the MIRACLE trial. PMID 41720449 · Cancer Lett · 2026-May-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Coronary Plaque Progression After Androgen Deprivation Therapy in Men With Prostate Cancer: A Randomized Clinical Trial. PMID 41706486 · JAMA Cardiol · 2026-May-01 This is a randomized, open-label Phase II trial (based on sample size and design, not explicitly Phase III) comparing GnRH agonist vs antagonist in men with prostate cancer. The primary endpoint is change in coronary plaque volume (a surrogate/imaging endpoint), not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. No Kaplan-Meier curves or hazard ratios for time-to-event outcomes are reported. It is a cardiovascular safety/biological study, not a definitive efficacy trial for oncologic endpoints. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Phase III cardiac rehabilitation improves left ventricular ejection fraction in patients with coronary artery disease and mildly reduced ejection fraction after percutaneous coronary intervention. PMID 41662912 · Int J Cardiol · 2026-May-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Generating the Evidence to Support Stereotactic Radiation Therapy Evolution: Challenges and a Roadmap for Progress. PMID 41651386 · Int J Radiat Oncol Biol Phys · 2026-May-01 The article is a review/commentary on the state of phase III trials in radiation oncology, not an original result report of a randomized trial with a drug intervention and a time-to-event endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Five-year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non-small-cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE-042 China study. PMID 41474069 · Int J Cancer · 2026-May-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 1 Figure · 4 Panel · risk unclear |
| Effects of Atrasentan on Kidney Gene Transcription, Mesangial Cell Proliferation, and Proteinuria in IgA Nephropathy. PMID 41442197 · Kidney360 · 2026-May-01 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Phase 3 randomized trial of postirradiation chemotherapy in patients with newly diagnosed ependymoma: A report from the Children's Oncology Group. PMID 41423745 · Neuro Oncol · 2026-May-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| The effects of lurasidone on five symptom domains and individual items in schizophrenia: Post-hoc analysis from Phase 3 study. PMID 41369302 · Int Clin Psychopharmacol · 2026-May-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Decitabine plus all-trans retinoic acid versus decitabine monotherapy for myelodysplastic syndromes with excess blasts: a multicenter, randomized controlled trial. PMID 41262042 · Haematologica · 2026-May-01 The record is a randomized, drug-intervention oncology trial with primary time-to-event (PFS, OS) results. However, the provided metadata (title, abstract, publication types, mesh terms) does not explicitly state the trial phase as Phase III, IIIb, or Phase II/III. The criteria require this phase to be explicitly established for eligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Marked survival gains in patients ≤ 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996-2020. PMID 41163573 · Haematologica · 2026-May-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 2 Figure · 8 Panel · risk visible |
| Segment 4b/5 Versus Wedge Resection for Gallbladder Adenocarcinoma: A Randomized Controlled Trial. PMID 40996213 · Ann Surg · 2026-May-01 The report is an eligible Phase III randomized trial with primary time-to-event efficacy endpoints (DFS and OS) in human oncology, but the intervention is purely surgical (liver resection techniques) and does not involve a drug-containing treatment arm, which is a mandatory criterion for inclusion. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Quality Assurance of Stereotactic Irradiation and Survival of Patients With Head and Neck Cancer in the GORTEC 2014-04 "OMET" Randomized Phase 2 Trial. PMID 40714135 · Int J Radiat Oncol Biol Phys · 2026-May-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Dosimetric Comparison of Magnetic Resonance Imaging Guided Versus Reduced Margin Computed Tomography Guided Stereotactic Body Radiation Therapy for Localized Prostate Cancer: Post Hoc Analysis of a Phase 3 Trial. PMID 40482729 · Int J Radiat Oncol Biol Phys · 2026-May-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Adjuvant VaccInation After Conization for the Treatment for CervicAL Dysplasia. PMID 40277212 · Eur J Cancer Prev · 2026-May-01 The record describes a prospective, likely non-randomized comparative study of adjuvant HPV vaccination after conization for cervical dysplasia. While it is oncology-related, human, includes a drug intervention (vaccine), and reports time-to-event outcomes with hazard ratios, it does not meet the required criteria for a Phase III/IIIb or Phase II/III randomized trial. The study design appears observational (counseled on vaccination, not randomly assigned), and the primary outcome is recurrence of HPV-related lesions/dysplasia, which is a precursor condition rather than a standard oncologic efficacy endpoint. The abstract explicitly notes that ongoing randomized trials are needed for more robust evidence, confirming this is not a definitive trial report. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Anti-PD-(L)1 plus chemotherapy in advanced PD-L1-negative nonsquamous non-small cell lung cancer: a systematic review and meta-analysis. PMID 42394449 · Immunotherapy · 2026-May 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Comparative efficacy of tislelizumab + FOLFOX or CAPOX for gastric/gastroesophageal junction adenocarcinoma: an exploratory matching-adjusted indirect comparison. PMID 42371751 · Curr Med Res Opin · 2026-May The record is an exploratory comparative efficacy analysis (matching-adjusted indirect comparison) synthesizing data from two existing trials (RATIONALE-305 and DisTinGuish). While it reports on randomized Phase III trials and includes a time-to-event endpoint (PFS), it is not itself a primary or original formal-result report of a single Phase III trial; it is a secondary analysis. The deterministic review correctly flagged unclear phase evidence, but the primary exclusion is the report type. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |